BLCO · Bausch & Lomb Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.24B | - | $1.28B | $1.28B | $1.14B | - | $1.20B | $1.22B | $1.10B | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $101.00M | - | $95.00M | $96.00M | $86.00M | - | $84.00M | $84.00M | $82.00M | - |
| SG&A | $544.00M | - | $528.00M | $579.00M | $563.00M | - | $511.00M | $535.00M | $504.00M | - |
| Total Operating Expenses | $1.21B | - | $1.19B | $1.29B | $1.22B | - | $1.15B | $1.19B | $1.09B | - |
| D&A | $101.00M | - | - | - | $106.00M | - | - | - | $110.00M | - |
| Operating Income | $33.00M | - | $95.00M | ($11.00M) | ($83.00M) | - | $43.00M | $26.00M | $6.00M | - |
| Interest Expense | $97.00M | - | $101.00M | $128.00M | $94.00M | - | $100.00M | $102.00M | $99.00M | - |
| Income Tax | $6.00M | - | $22.00M | ($89.00M) | $31.00M | - | ($66.00M) | $72.00M | $73.00M | - |
| Net Income | ($71.00M) | - | ($28.00M) | ($62.00M) | ($212.00M) | - | $4.00M | ($151.00M) | ($167.00M) | - |
| EPS - Basic | ($0.20) | - | ($0.08) | ($0.18) | ($0.60) | - | $0.01 | ($0.43) | ($0.48) | - |
| EPS - Diluted | ($0.20) | - | ($0.08) | ($0.18) | ($0.60) | - | $0.01 | ($0.43) | ($0.48) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $268.00M | $383.00M | $310.00M | $266.00M | $202.00M | $305.00M | $329.00M | $285.00M | $315.00M | $331.00M |
| Accounts Receivable | $1.11B | $1.22B | $1.09B | $1.08B | $1.01B | $1.03B | $943.00M | $986.00M | $920.00M | $839.00M |
| Inventory | $977.00M | $976.00M | $1.00B | $1.05B | $1.03B | $1.04B | $1.12B | $1.07B | $1.07B | $1.03B |
| Accounts Payable | $407.00M | $388.00M | $395.00M | $449.00M | $427.00M | $389.00M | $455.00M | $405.00M | $426.00M | $522.00M |
| Current Assets | $2.78B | $2.98B | $2.85B | $2.85B | $2.69B | $2.79B | $2.83B | $2.77B | $2.74B | $2.74B |
| Total Assets | $13.78B | $14.02B | $13.83B | $13.83B | $13.43B | $13.47B | $13.52B | $13.25B | $13.29B | $13.44B |
| Current Liabilities | $1.82B | $1.92B | $1.90B | $1.84B | $1.73B | $1.74B | $1.80B | $1.68B | $1.62B | $1.58B |
| Long-term Debt | $5.01B | $5.02B | $4.92B | $4.93B | $4.79B | $4.74B | $4.60B | $4.60B | $4.55B | $4.53B |
| Total Liabilities | $7.33B | $7.50B | $7.33B | $7.32B | $7.00B | $6.92B | $6.85B | $6.67B | $6.56B | $6.52B |
| Stockholders' Equity | $6.38B | $6.45B | $6.43B | $6.44B | $6.36B | $6.47B | $6.59B | $6.50B | $6.66B | $6.85B |
| Retained Earnings | ($1.00B) | ($931.00M) | ($873.00M) | ($845.00M) | ($783.00M) | ($571.00M) | ($568.00M) | ($572.00M) | ($421.00M) | ($254.00M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $32.00M | - | - | - | ($25.00M) | - | - | - | $41.00M | - |
| Investing Cash Flow | ($130.00M) | - | - | - | ($116.00M) | - | - | - | ($57.00M) | - |
| Financing Cash Flow | ($20.00M) | - | - | - | $31.00M | - | - | - | $12.00M | - |
| CapEx | $100.00M | - | - | - | $110.00M | - | - | - | $67.00M | - |
| Free Cash Flow | ($68.00M) | - | - | - | ($135.00M) | - | - | - | ($26.00M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 2.7% | - | 7.4% | -0.9% | -7.3% | - | 3.6% | 2.1% | 0.5% | - |
| EBITDA margin | 10.8% | - | - | - | 2.0% | - | - | - | 10.6% | - |
| Net margin | -5.7% | - | -2.2% | -4.9% | -18.6% | - | 0.3% | -12.4% | -15.2% | - |
| Free cash flow margin | -5.5% | - | - | - | -11.9% | - | - | - | -2.4% | - |
| FCF / Net income | 0.96 | - | - | - | 0.64 | - | - | - | 0.16 | - |
| R&D / Revenue | 8.1% | - | 7.4% | 7.5% | 7.6% | - | 7.0% | 6.9% | 7.5% | - |
| SG&A / Revenue | 43.7% | - | 41.2% | 45.3% | 49.5% | - | 42.7% | 44.0% | 45.9% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -0.5% | - | -0.2% | -0.4% | -1.6% | - | 0.0% | -1.1% | -1.3% | - |
| Return on equity | -1.1% | - | -0.4% | -1.0% | -3.3% | - | 0.1% | -2.3% | -2.5% | - |
| Return on invested capital | 0.2% | - | 0.7% | -0.1% | -0.6% | - | 0.3% | 0.2% | 0.0% | - |
| Liquidity | ||||||||||
| Current ratio | 1.53 | 1.55 | 1.51 | 1.55 | 1.56 | 1.60 | 1.57 | 1.65 | 1.70 | 1.74 |
| Quick ratio | 0.99 | 1.04 | 0.98 | 0.98 | 0.96 | 1.01 | 0.95 | 1.01 | 1.03 | 1.09 |
| Cash ratio | 0.15 | 0.20 | 0.16 | 0.14 | 0.12 | 0.18 | 0.18 | 0.17 | 0.19 | 0.21 |
| Leverage | ||||||||||
| Debt / Equity | 0.79 | 0.78 | 0.77 | 0.77 | 0.75 | 0.73 | 0.70 | 0.71 | 0.68 | 0.66 |
| Debt / Assets | 0.36 | 0.36 | 0.36 | 0.36 | 0.36 | 0.35 | 0.34 | 0.35 | 0.34 | 0.34 |
| Debt / EBITDA | 37.40 | - | - | - | 208.22 | - | - | - | 39.26 | - |
| Interest coverage | 0.3x | - | 0.9x | -0.1x | -0.9x | - | 0.4x | 0.3x | 0.1x | - |
| Equity multiplier | 2.16 | 2.17 | 2.15 | 2.15 | 2.11 | 2.08 | 2.05 | 2.04 | 2.00 | 1.96 |
| Liabilities / Assets | 0.53 | 0.54 | 0.53 | 0.53 | 0.52 | 0.51 | 0.51 | 0.50 | 0.49 | 0.49 |
| Efficiency | ||||||||||
| Asset turnover | 0.09 | - | 0.09 | 0.09 | 0.08 | - | 0.09 | 0.09 | 0.08 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 325d | - | 310d | 310d | 323d | - | 288d | 296d | 306d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | 1929.0x | - | - | - |
| P / B | 0.9x | - | 0.8x | 0.7x | 0.8x | - | 1.0x | 0.8x | 0.9x | - |
| P / S | 4.5x | - | 4.2x | 3.6x | 4.5x | - | 5.7x | 4.2x | 5.5x | - |
| EV / EBITDA | 77.5x | - | - | - | 421.9x | - | - | - | 88.9x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 9.4% | - | 7.1% | 5.1% | 3.5% | - | 18.8% | 17.5% | 18.0% | - |
| Revenue CAGR (3y) | 10.1% | - | 10.8% | 10.7% | 8.5% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | 120.9% | - | - | - | 7.5% | -39.5% | - | - |
| Net income growth (YoY) | 66.5% | - | - | 58.9% | -26.9% | - | - | -371.9% | -85.6% | - |
| EPS growth (YoY) | 66.7% | - | - | 58.1% | -25.0% | - | - | -377.8% | -84.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 49.6% | - | - | - | -419.2% | - | - | - | 72.0% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 0.3% | -0.4% | -2.4% | -1.0% | -4.5% | -5.5% | -3.3% | -6.5% | -4.6% | -2.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$5.10B totalVision Care$2.92B · 57.3%
Pharmaceuticals$1.28B · 25.2%
Surgical$894.00M · 17.5%
Product / service
$8.02B totalProduct$5.08B · 63.3%
Overthe Counter Products$1.83B · 22.9%
Device Products$1.03B · 12.9%
Brandedand Other Generic Products$42.00M · 0.5%
Product And Service Other$21.00M · 0.3%
Other Revenues$9.00M · 0.1%
Pharmaceutical Products$5.00M · 0.1%
Geographic
$5.10B totalUnited Statesand Puerto Rico$2.55B · 49.9%
Other Countries$777.00M · 15.2%
CN$358.00M · 7.0%
FR$246.00M · 4.8%
JP$186.00M · 3.6%
DE$164.00M · 3.2%
RU$148.00M · 2.9%
GB$137.00M · 2.7%
CA$135.00M · 2.6%
IT$102.00M · 2.0%
ES$101.00M · 2.0%
MX$75.00M · 1.5%
PL$75.00M · 1.5%
KR$51.00M · 1.0%
Peer comparison
Same SIC group: Ophthalmic Goods
Comparing Bausch & Lomb Corp against the 5 most active filers in the same SIC group.